Our recommendation – don’t sell

The offer prospectus was published Friday, and we did not find anything that changed our position, but there are some interesting findings (spoiler: a lot of added cost).

In the following one-pager we summarize what we have learned from the prospectus and the reasons for our recommendation to other Crayon shareholders; don’t sell.

If you want to read the in dept analysis, check it out here: “Beauty and the Beast”.
Our peer analysis sent out last week will also give insight on the fact that Crayon delivers best among peers, and SWON is at the other end of the scale.

Best regards,
David and Sverre

Hvaler Invest AS
Lillestrøm, Norway
17.03.25

Disclaimer:
Hvaler Invest is a significant shareholder so you cannot trust us (or perhaps you can?)